

Table S2. Characteristics of the persons in the study cohorts.

| | Statin No (%) (n=40254) | Hypertension No (%) (n=41610) | Population No (%) (n=62585) |
|--|--|--|--|
| During the exposure period | | | |
| Alcohol-related hospitalisation | 4 (0.01) | 11 (0.03) | 16 (0.03) |
| Use of bisphosphonates (mevalonate pathway)* | 2226 (5.53) | 2004 (4.82) | 1833 (2.93) |
| Insulin and other blood glucose lowering drugs | 7393 (18.37) | 4021 (9.66) | 2239 (3.58) |
| Diuretics | 10666 (26.50) | 12832 (30.84) | 5632 (9.00) |
| Beta blocking agents | 21815 (54.19) | 23684 (56.92) | 9765 (15.60) |
| Calcium channel blockers | 9751 (24.22) | 11165 (26.83) | 4260 (6.81) |
| Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers | 15383 (38.17) | 20325 (48.85) | 7736 (12.36) |
| During the 365 days prior to the follow-up | | | |
| Use of antipsychotics, anxiolytics, hypnotics, sedatives, non-selective monoamine-reuptake inhibitors, monoamine oxidase type A inhibitors, or other antidepressants | 9770 (24.27) | 9034 (21.71) | 8390 (13.41) |

* Pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, risendronic acid in combination preparation with calcium, or risedronic acid with calcium and cholecalciferol